221
Participants
Start Date
October 31, 2011
Primary Completion Date
December 31, 2013
Study Completion Date
December 31, 2013
secukinumab (AIN457)
"Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17)."
placebo
Matching placebo to AIN457 i.v. and to AIN457 s.c..
Novartis Investigative Site, Budapest
Novartis Investigative Site, Sofia
Novartis Investigative Site, Sofia
Novartis Investigative Site, Sofia
Novartis Investigative Site, Plovdiv
Novartis Investigative Site, Plovdiv
Novartis Investigative Site, Debrecen
Novartis Investigative Site, Sevlievo
Novartis Investigative Site, Pleven
Novartis Investigative Site, Torino
Novartis Investigative Site, Arenzano
Novartis Investigative Site, Genova
Novartis Investigative Site, Vestavia Hills
Novartis Investigative Site, Valeggio sul Mincio
Novartis Investigative Site, Nashville
Novartis Investigative Site, Jackson
Novartis Investigative Site, Tupelo
Novartis Investigative Site, Bowling Green
Novartis Investigative Site, Siena
Novartis Investigative Site, Lincoln
Novartis Investigative Site, Peoria
Novartis Investigative Site, Trnava
Novartis Investigative Site, Upland
Novartis Investigative Site, Piešťany
Novartis Investigative Site, Topoľčany
Novartis Investigative Site, Partizánske
Novartis Investigative Site, Lučenec
Novartis Investigative Site, St. John's
Novartis Investigative Site, Sainte-Foy
Novartis Investigative Site, Szeged
Novartis Investigative Site, Roma
Novartis Investigative Site, Bialystok
Novartis Investigative Site, Poznan
Novartis Investigative Site, Warsaw
Novartis Investigative Site, Warsaw
Novartis Investigative Site, San Juan
Novartis Investigative Site, Bardejov
Novartis Investigative Site, Sabinov
Novartis Investigative Site, Stará Ľubovňa
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY